抗体生産市場規模、シェア、成長分析、製品別、プロセス別、タイプ別、最終用途別、地域別 - 産業別予測、2024～2031年

抗体生産の世界市場規模は、2022年に164億米ドルと評価され、2023年の185億2,000万米ドルから2031年には488億8,000万米ドルに成長し、予測期間中（2024-2031年）のCAGRは12.9％で成長する見通しです。

抗体生産市場は、標的治療、診断、ワクチンに不可欠な抗体需要の高まりによって著しい成長を遂げています。バイオテクノロジーの進歩と分子疾患メカニズムの深い理解により、研究や個別化医療に使用される特異的で効果的な抗体の必要性が高まっています。慢性疾患や感染症の流行は、特にがんや自己免疫疾患などの治療において、この需要を牽引し続けています。生産効率と拡張性を高める組換えDNA技術やハイスループットスクリーニングなどの技術革新により、機会は豊富にあります。この市場はヘルスケア産業において重要な役割を果たしており、進化するニーズに適応する一方で、精密医療へのシフトの高まりに対応して技術革新と拡大を促進しています。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次データと一次データの方法
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 世界市場の見通し
• 供給と需要の動向分析
• セグメント別機会分析

市場力学と見通し

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーターの分析

主な市場の考察

• 重要成功要因
• 競合の程度
• 主な投資機会
• 市場エコシステム
• 市場の魅力指数（2023年）
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析
• 規制分析
• ケーススタディ分析
• 特許分析

抗体生産市場規模：製品別

• 市場概要
• 機器
  • バイオリアクター
  • 多目的バイオリアクター
  • 使い捨てバイオリアクター
  • その他
• クロマトグラフィーシステム
• 濾過システム
• 消耗品
  • メディア
  • 緩衝液と試薬
  • クロマトグラフィー樹脂とカラム
  • 濾過消耗品および付属品
  • その他
• ソフトウェア

抗体生産市場規模：プロセス別

• 市場概要
• 上流処理
• 下流処理

抗体生産市場規模：タイプ別

• 市場概要
• ポリクローナル抗体
• モノクローナル抗体

抗体生産市場規模：最終用途別

• 市場概要
• 製薬・バイオテクノロジー企業
• 調査室
• CROSとCDMOS

抗体生産市場規模

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2023年）
• 主な市場企業が採用した戦略
• 市場の最近の動向
• 企業の市場シェア分析（2023年）
• 主要企業の企業プロファイル
  • 会社概要
  • 製品ポートフォリオ分析
  • セグメント別シェア分析
  • 収益の前年比比較（2021-2023）

主要企業プロファイル

• Roche（Switzerland）
• Genmab（Denmark）
• Amgen（US）
• Biogen（US）
• Johnson & Johnson（US）
• AbbVie（US）
• AstraZeneca（UK）
• Novartis（Switzerland）
• Pfizer（US）
• Sanofi（France）
• Merck & Co.（US）
• Gilead Sciences（US）
• Celgene（US）
• BioMarin Pharmaceutical（US）
• Shire（Ireland）
• Alexion Pharmaceuticals（US）
• Teva Pharmaceuticals（Israel）
• Allergan（US）
• Bristol Myers Squibb（US）
• Novo Nordisk（Denmark）

結論と推奨事項

Global Antibody Production Market size was valued at USD 16.4 billion in 2022 and is poised to grow from USD 18.52 billion in 2023 to USD 48.88 billion by 2031, growing at a CAGR of 12.9% during the forecast period (2024-2031).

The antibody production market is witnessing significant growth, spurred by the rising demand for antibodies essential in targeted therapies, diagnostics, and vaccines. Advances in biotechnology and a deeper understanding of molecular disease mechanisms have heightened the need for specific and effective antibodies used in research and personalized medicine. The prevalence of chronic and infectious diseases continues to drive this demand, particularly for treatments in cancer, autoimmune disorders, and other conditions. Opportunities abound due to technological innovations, including recombinant DNA technology and high-throughput screening, which enhance production efficiency and scalability. This market plays a crucial role in the healthcare industry, adapting to evolving needs while fostering innovation and expansion in response to the increasing shift towards precision medicine.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Antibody Production market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Antibody Production Market Segmental Analysis

Global Antibody Production Market is segmented by product, process, type, end use and region. Based on product, the market is segmented into instruments, chromatography systems, filtration systems, consumables and software. Based on process, the market is segmented into upstream processing and downstream processing. Based on type, the market is segmented into polyclonal antibody and monoclonal antibody. Based on end use, the market is segmented into pharmaceutical and biotechnology companies, research laboratories and cros and cdmos. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Antibody Production Market

The Global Antibody Production market is significantly driven by the escalating demand for antibody-based therapeutics, propelled by the rising incidence of chronic diseases and the widespread adoption of targeted treatment strategies. Antibodies are prized for their precision and effectiveness in managing a variety of health conditions, including cancer, autoimmune disorders, and infectious diseases. The emergence and application of monoclonal antibodies (mAbs) have transformed treatment modalities, leading to numerous blockbuster medications originating from antibody therapies. This increasing emphasis on specialized and efficient therapeutic options continues to bolster the market, reflecting the critical role of antibodies in modern medicine.

Restraints in the Global Antibody Production Market

The Global Antibody Production market faces significant restraints due to high development and production costs. The intricate processes involved in antibody development, coupled with extensive research and the need for expansive manufacturing facilities, lead to elevated expenses that can burden small and medium-sized enterprises. This cost-intensive nature of antibody production creates barriers to entry and diminishes the affordability and accessibility of antibody-based therapies, ultimately hampering market expansion. As a result, these economic challenges pose a substantial obstacle to growth within the industry, making it difficult for smaller players to compete and innovate in this evolving market landscape.

Market Trends of the Global Antibody Production Market

The Global Antibody Production market is witnessing a significant market trend driven by the increasing focus on personalized medicine. As healthcare systems shift towards more tailored treatment approaches, antibody production plays a pivotal role in creating targeted therapies designed to meet the unique needs of individual patients. Recent advancements in genomic and proteomic technologies have streamlined the identification of specific disease markers, enhancing the ability to design and manufacture antibodies that precisely target these markers. This alignment with personalized medicine not only fosters improved patient outcomes but also stimulates growth in the antibody production sector, as stakeholders increasingly prioritize customized therapeutic solutions.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2023
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Analysis
• Case Study Analysis
• Patent Analysis

Global Antibody Production Market Size by Product & CAGR (2024-2031)

• Market Overview
• Instruments
  • Bioreactors
  • Multi-Use Bioreactors
  • Single-Use Bioreactors
  • Others
• Chromatography Systems
• Filtration Systems
• Consumables
  • Media
  • Buffers and Reagents
  • Chromatography Resins and Columns
  • Filtration Consumables and Accessories
  • Others
• Software

Global Antibody Production Market Size by Process & CAGR (2024-2031)

• Market Overview
• Upstream Processing
• Downstream Processing

Global Antibody Production Market Size by Type & CAGR (2024-2031)

• Market Overview
• Polyclonal Antibody
• Monoclonal Antibody

Global Antibody Production Market Size by End Use & CAGR (2024-2031)

• Market Overview
• Pharmaceutical and Biotechnology Companies
• Research Laboratories
• CROS and CDMOS

Global Antibody Production Market Size & CAGR (2024-2031)

• North America (Product, Process, Type, End Use)
  • USA
  • Canada
• Europe (Product, Process, Type, End Use)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product, Process, Type, End Use)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product, Process, Type, End Use)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product, Process, Type, End Use)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2023
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2021-2023)

Key Company Profiles

• Roche (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Genmab (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biogen (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Celgene (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioMarin Pharmaceutical (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Shire (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alexion Pharmaceuticals (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceuticals (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Allergan (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novo Nordisk (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations